# Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial

> **NCT06670963** · PHASE4 · RECRUITING · sponsor: **Piotr Czempik** · enrollment: 200 (estimated)

## Conditions studied

- Anemia
- Sepsis
- Septic Shock

## Interventions

- **DRUG:** Iron
- **DRUG:** EPO
- **DRUG:** 0.9 % NaCl

## Key facts

- **NCT ID:** NCT06670963
- **Lead sponsor:** Piotr Czempik
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-04-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06670963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06670963, "Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06670963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*